Farmaceutica REMEDIA S.A.

1st Semester 2026 CONSOLIDATED REPORT

Board of Administrators of
Farmaceutica REMEDIA S.A.

Farmaceutica REMEDIA S.A.
Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197
Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640
remedia@remedia.ro, www.remedia.ro
Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 9.548.082
IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest
IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

1st SEMESTER 2026 CONSOLIDATED REPORT
According to F.S.A. Regulation No. 5/2018
Date of the report: 26.08.2026

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**
Paid-up share capital: **9.548.082 Lei**
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd.**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration
with the Trade Register Office: **J20/700/25.07.1991**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(**Registration certificate No. AC-1470-7/17.06.2021**)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **0,10 Lei**
Position in FSA Register: **1636**
Total number: **95.480.820**
FSA code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010.70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	TOTAL	**95.480.820**	**9.548.082,00 Lei**

Organized market on which securities are traded:
Bucharest Stock Exchange - Standard category
The total market value on 26.08.2026 is of 84.023.121 Lei, at a value of a 0,88 Lei/RMAH share

1. Important events to report

During the reporting period, Remedia completed the installation of a new pharmacy robot in Jibou. As a result, the company's in-house technical team has now installed and commissioned a total of 26 units, consolidating the company's position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

2. The general description of the financial position and of the issuer's performances and of its branches related to the 1st semester 2026

During the period 01.01.2026 – 30.06.2026, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-June 2026 (Lei)	Realisations Jan-June 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	341.980.070	362.434.169	-5,64%
2.	Other operating revenues	3.965.585	5.647.594	-29,78%
3.	Total operating income	345.945.655	368.081.762	-6,01%
4.	Total operational costs *	344.167.695	359.914.258	-4,38%
5.	Operating result	1.777.960	8.167.504	-78,23%
6.	Financial result	1.037.499	674.396	53,84%
7.	Gross result	2.815.459	8.841.900	-68,16%

* Including trade discounts granted/received

A breakdown of sales of goods by segments of activity is presented as follows:
Lei

REMEDIA Pharmacies	4.862.634	1,40%
Distribution	244.761.729	71,60%
Hospitals & Private Clinics Distribution	92.094.430	26,90%
BD Rowa robots	261.277	0,10%
Total	**341.980.070**	**100,00 %**

"Other operating revenues" mainly comprise the following categories of revenues:

- collected rents
- BD Rowa services

3. The financial statements as of 30.06.2026 were not audited by the independent financial auditor.

4. Economic-Financial Indicators as of 30.06.2026

LIQUIDITY AND WORKING CAPITAL	FR	FRDL
Current liquidity (Current assets / Current debts)	3,07	1,05
Current assets	20.737.378	273.319.154
Current debts	6.753.456	260.896.206
Degree of indebtedness (Borrowed capital / Equity x 100)	0	0%
Borrowed capital	0	0
Equity	56.207.959	18.652.922
Turnover speed for client debit items (Average customer balance /turnover *180)	141 days	99 days
Average customer balance	2.754.543	190.126.316
Net turnover	3.527.879	343.968.762
Turnover speed of stocks (average stock/ net COGS)*180	486 days	32 days
Average stock	967.199	56.672.529
COGS net	358.273	316.205.786

*including financial leasing

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors in case of FR and FRDL, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of FR and FRDL there is no risk at all. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specifics of receivables in the distribution of medicines, we consider that the value of the indicator is normal for the companies from the group, under the given conditions.

4) The value of the indicator **No. of days of storage** can be regarded as falling within the scope of the business's specific operations, being influenced, in the case of FR, by the high level of stock represented by the BD Rowa robot. This is purchased exclusively on the basis of a firm order and an accepted quotation.

26.08.2026

Board of Administrators

Chairman

"TARUS" Valentin-Norbert TARUS e.U.
1020 Viena, Leopold-Moses Gasse, 4/42/6, Austria

FN 349134h/23.07.2010

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

	30.06.2026	30.06.2025
Net turnover	**345.806.277**	**366.052.207**
Income from the sale of goods	343.267.252	363.799.384
Commercial discounts granted	-1.287.182	-1.365.216
Income from services provided and rents	3.826.208	3.618.039
Income from real estate investments		**0**
Other operating income	**139.378**	**2.029.555**
OPERATING INCOME - TOTAL	**345.945.655**	**368.081.762**
Expenses with materials	**317.825.927**	**336.577.647**
Expenses regarding goods	330.165.776	344.602.211
Commercial discounts received	-13.761.706	-9.348.830
Expenses with raw materials and consumables	821.507	757.588
Other expenses with materials (inventory objects)	74.078	49.363
Energy and water expenses	526.272	517.315
Expenses with personnel	**12.910.780**	**11.904.969**
Salaries and allowances	10.944.883	10.251.553
Expenses with insurance and social protection	405.869	511.236
Other personnel expenses	1.560.028	1.142.180
Amortisations and provisions	**1.418.034**	**844.734**
Amortisations	1.377.646	1.142.956
Net provisions	-37.184	-520.813
Losses from receivables	77.571	222.591
Other operating expenses	**12.012.954**	**10.586.908**
Expenses on external services	10.668.426	8.727.264
Expenses with other taxes, charges and assimilated payments	1.150.692	958.508
Other expenses	193.836	901.136
OPERATING EXPENSES - TOTAL	**344.167.695**	**359.914.258**
OPERATING RESULT	**1.777.960**	**8.167.504**
Financial income	**1.290.531**	**1.038.465**
Interest income	773.458	643.881
Income from exchange rate differences	204.345	161.575
Income from dividends	78.468	0
Advance payment discounts	32.796	145.773
Other financial income		
Other financial revenues share of the loss from investments accounted for using the equity method	201.465	87.236
Financial expenses	**253.032**	**364.069**
Expenses regarding interests leasing	0	1.199
Operational leasing interests	22.112	81.373
Expenses due to exchange rate differences	230.920	281.497
Discounts received in advance	0	0
Other financial expenses	0	0
Other financial expenses - share of the loss from investments accounted for using the equity method	0	0
FINANCIAL RESULT	**1.037.499**	**674.396**

TOTAL INCOME	**347.236.186**	**369.120.228**
TOTAL EXPENSES	**344.420.727**	**360.278.328**
GROSS RESULT	**2.815.459**	**8.841.900**
Profit tax	1.682.471	3.657.451
TOTAL NET PROFIT of which distributable	**1.132.988**	**5.184.449**
Shareholders of the company	**1.132.988**	**5.184.449**
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which attributable:	**1.132.988**	**5.184.449**
Shareholders of the company	**1.132.988**	**5.184.449**
Minority interest		
Earnings per share (in Lei)		
- basic	0,0119	0,0543
- diluted	0,0119	0,0543

* retreated according to IFRS 16

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

	30.06.2026	31.12.2025
ASSETS		
Fixed assets	**51.555.057**	**51.617.337**
Tangible assets	31.238.348	31.180.789
Real estate investments	17.778.668	17.778.668
Assets related to the rights of use of leased assets	541.437	710.173
Software licences	966.633	1.028.279
Pharmacy licences	273.382	424.520
Participations held in group companies	0	0
Participations held in companies outside the group	130.286	130.286
Investments in jointly controlled entities accounted for using the equity method	366.420	164.955
Deposits and guarantees paid	259.883	199.668
Current assets	**292.848.017**	**331.298.467**
Stocks	50.903.909	63.371.504
Advances granted for the purchase of stocks	2.903	2.063
Trade receivables	196.542.733	205.038.726
Other receivables	6.875.290	4.947.298
Cash and cash equivalents	38.523.182	57.938.876
Accrued expenses	**915.084**	**269.736**
TOTAL ASSETS	**345.318.157**	**383.185.541**
EQUITIES AND DEBTS		
Equities	**73.500.251**	**79.610.034**
Share capital	9.548.082	9.548.082
Share premiums	757.485	757.485
Reserves	20.099.711	17.726.280
Revaluation reserves	30.526.555	30.526.555
Current result	1.132.988	8.038.123
Retained earnings	16.765.886	18.881.235
Retained earnings - retreatment	-638.931	-775.278
Profit distribution	0	0
Own shares	-1.316.108	-1.316.108
Losses related to the issuance, redemption, sale, free transfer or cancellation of equity instruments	-107.727	-107.727
Employee benefits in the form of equity instruments	469.630	68.708
Other equity items	-3.737.321	-3.737.321
Long-term debts	**5.218.196**	**5.213.138**
Debts from long term operational leasing	421.720	416.662
Provisions		
Debts with deferred income tax	4.796.476	4.796.476
Current debts	**266.599.710**	**298.362.368**
Bank loans		
Debts from financial leasing		
Debts from operational leasing	160.064	333.866

Suppliers and other similar debts	254.070.906	291.624.623
Provisions	0	562.278
Current tax debts	827.152	2.369.475
Other short-term debts	11.285.999	3.216.538
Deferred income tax liabilities	255.588	255.588
Total debts	**271.817.906**	**303.575.506**
TOTAL EQUITIES AND DEBTS	**345.318.157**	**383.185.540**

* retreated according to IFRS 16

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25th 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13th 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1st 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1st 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **April 2022**, Farmaceutica REMEDIA SA purchased a 50% participation in the share capital of the Romanian legal entity PHARMA EXPERTSPEDITION S.R.L., with registered office in Bucharest, Bd. Metalurgiei, nr. 130E, Sector 4, registered at the Commercial Register of Bucharest with nr. J40/20206/2005, with TIN 18178346, in order to develop and strengthen the distribution and logistics activity.

In **January 2025**, Farmaceutica REMEDIA SA (FR) acquired 24 per cent of the share capital of SC Novoengrama SRL, a company specialising in medical rehabilitation, which operates in the city of Cluj-Napoca.

In this context, **on 30.06.2026** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

During the first half of 2026 Farmaceutica REMEDIA S.A. did not participate in mergers.

During the same period, the company did not alienate assets of significant value (buildings, land, shares, etc.).

During the reporting period, Remedia completed the installation of a new pharmacy robot in Jibou. As a result, the company's in-house technical team has now installed and commissioned a total of 26 units, consolidating the company's position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the

European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counter-performance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
  Segment reporting
- Retreatment of operational leasing contracts according to IFRS 16

The company holds participations in other companies, in one of them having the control over the financial and operational policies. An entity is consolidated if, based on the assessment of its relations with the Company, it is found that it is controlled by the Company.

The companies whose financial statements are consolidated are:

- Farmaceutica REMEDIA S.A.
- Farmaceutica REMEDIA Distribution & Logistics S.R.L.
- PHARMA EXPERTSPEDITION SRL, a company in which **Farmaceutica REMEDIA S.A. holds 50% of the share capital, using the equity method**

Starting with 2012, for the class of tangible assets « Lands and buildings », the Company passed from the cost-based accounting model to the reassessment model.

The consolidated financial statements on 30.06.2026 were not audited by the independent financial auditor.

NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

During the period 01.01.2026 – 30.06.2026, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Jun 2026 (Lei)	Realisations Jan-Jun 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	341.980.070	362.434.169	-5,64%
2.	Other operating revenues	3.965.585	5.647.594	-29,78%
3.	Total operating revenues	345.945.655	368.081.762	-6,01%
4.	Total operating costs *	344.167.695	359.914.258	-4,38%
5.	Operating result	1.777.960	8.167.504	-78,23%
6.	Financial result	1.037.499	674.396	53,84%
7.	Gross result	2.815.459	8.841.900	-68,16%

* Including commercial discounts granted/received

"Other operating revenues" mainly comprise the following categories of revenues:
- collected rents
- BD Rowa services

A breakdown of sales of goods by segments of activity is presented as follows:
Lei

REMEDIA Pharmacies	4.862.634	1,40%
Distribution	244.761.729	71,60%
Hospitals & Clinics Distribution	92.094.430	26,90%
BD Rowa robots	261.277	0,10%
Total	**341.980.070**	**100,00 %**

NOTA 4 ECONOMIC-FINANCIAL INDICATORS

LIQUIDITY AND WORKING CAPITAL	FR	FRDL
Current liquidity (Current assets / Current debts)	3,07	1,05
Current assets	20.737.378	273.319.154
Current debts	6.753.456	260.896.206
Degree of indebtedness (Borrowed capital / Equity x 100)	0	0%
Borrowed capital	0	0
Equity	56.207.959	18.652.922
Turnover speed for client debit items (Average customer balance /turnover *180)	141 zile	99 zile
Average customer balance	2.754.543	190.126.316
Net turnover	3.527.879	343.968.762
Turnover speed of stocks (average stock/ net COGS)*180	486 zile	32 zile
Average stock	967.199	56.672.529
COGS net	358.273	316.205.786

*including financial leasing

__Notes__:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors in case of FR and FRDL, certifying that the company is able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of FR and FRDL there is no risk at all. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specifics of receivables in the distribution of medicines, we consider that the value of the indicator is normal for the companies, under the given conditions.

4) The value of the indicator **No. of days of storage** is in line with the nature of the company's business, being influenced by the high value of the stock represented by the BD Rowa robot. This is purchased exclusively on the basis of a firm order and an accepted quotation.

Note 5 Reporting on activity segments (consolidated)

			Hospitals &	Distribution	REMEDIA Pharmacies	Services	BD ROWA	TOTAL *
			Clinics			Provided	Robots	2026
					E-commerce	and rents		
Net turnover			**92.094.430**	**244.761.729**	**4.862.634**	**3.471.241**	**616.242**	**345.806.276**
	Income from the sale of goods		92.094.430	246.048.911	4.862.634	0	261.276	**343.267.252**
	Commercial discounts granted		0	1.287.182	**0**	0		**-1.287.182**
	Income from services provided and rents				**0**	3.471.241	354.966	**3.826.208**
Other operating income			0	130.084	**9.183**	111		**139.378**
OPERATING INCOME - TOTAL			**92.094.430**	**244.891.813**	**4.871.817**	**3.471.352**	**616.242**	**345.945.655**
Expenses with goods			**91.180.575**	**221.191.913**	**3.916.012**	**0**	**115.571**	**316.404.071**
	Expenses regarding goods		98.566.161	227.568.032	3.916.012		115.571	**330.165.776**
	Commercial discounts received		-7.385.586	-6.376.119	0	0		**-13.761.706**
Gross margin from sales of goods			**913.855**	**23.699.901**	**955.805**	**3.471.352**	**145.704**	**29.541.584**
								0
Other operating costs			**2.844.801**	**21.001.906**	**2.084.552**	**882.346**	**950.018**	**27.763.624**
	Direct costs		2.098.501	14.307.703	1.633.470	635.758	919.206	**19.594.638**
	Logistics costs		315.383	2.803.759	**31.538**			**3.150.681**
	Indirect costs		430.917	3.890.444	419.544	246.588	30.812	**5.018.305**
OPERATING EXPENSES - TOTAL			**94.025.376**	**242.193.819**	**6.000.564**	**882.346**	**1.065.589**	**344.167.695**
								0
Operating result			**-1.930.946**	**2.697.995**	**-1.128.747**	**2.589.006**	**-449.348**	**1.777.960**
Financial result								**1.037.499**
Gross result								**2.815.459**
	Profit tax							-1.682.471
Net profit								**1.132.988**

NOTE 6 CAPITALS CHANGES

consolidated	Share	Legal	Revaluation	Other	Employee benefits granted	Other equity components	Share	Retained	Current	Own	TOTAL
	capital	reserves	reserves	reserves	in the form of equity instruments		premiums	earnings	result	shares	2026
Balance on 01.01.2026	9.548.082	2.122.356	30.526.554	15.603.926	68.708	-3.737.321	757.485	18.105.957	8.038.123	-1.423.835	**79.610.034**
Restoration of profit account retreatments 2025								-4.585.670	4.585.670		**0**
Profit transfer 2025 (FR) to retained earnings								7.067.746	-7.067.746		**0**
Profit distribution 2025(FR) to dividends				0				-4.694.314			**-4.694.314**
Profit distribution 2025(FR) to other reserves				2.373.431				-2.373.431			**0**
Account closure 129											**0**
Profit transfer 2025(FRDL) to retained earnings								5.556.047	-5.556.047		**0**
Profit distribution 2025(FRDL) to dividends								-3.500.000			**-3.500.000**
Profit distribution 2025(FRDL) to other reserves				0							**0**
Accounting result 2026 FR + FRDL									1.927.811		**1.927.811**
Profit account retreatment								794.822	-794.822		**0**
Buildings + lands outputs			0								**0**
Revaluation of buildings and lands											**0**
Transfer reserves from funds											**0**
Reported results - retreating								-141.092			**-141.092**
Buy own shares											**0**
Deferred tax											**0**
Retreatment of operational leasing (IFRS 16)								-37.994			**-37.994**
Investments in jointly controlled entities											**0**
Losses from the free transfer of own shares										0	**0**
Transfer of deferred tax from the revaluation											**0**
Accounting adjustments								-65.117			**-65.117**
Reserves – employee share plan (IFRS 2)					400.923						**400.923**
Balance on 30.06.2026	**9.548.082**	**2.122.356**	**30.526.554**	**17.977.357**	**469.630**	**-3.737.321**	**757.485**	**16.126.955**	**1.132.988**	**-1.423.835**	**73.500.251**

NOTE 7 TREASURY FLOWS STATEMENT (RON) (consolidated)

	30/06/2026
Cash flows from operating activities	
Collections from the sale of goods and from the provision of services	394.424.315
Other cash inflows	14.464.031
Payments to suppliers of goods and services	-391.280.942
Payments to and on behalf of employees (incl. taxes on salaries)	-11.122.420
Corporate tax payments	-3.264.878
Payments to other taxes and fees	-22.028.676
Paid interests	0
Collected interests (current account)	771.054
Other cash outflows	-567.092
Total operating cash flow	**-18.604.607**
Cash flow from investment activities	0
Proceeds from the sale of long-term assets and financial investments	6.937
Collected interests (from deposits)	0
Collected dividends	78.468
Payments for the purchase of long-term assets	-929.961
Total cash flow from investments	**-844.556**
Cash flow from financing activities	**33.469**
Short-term loan withdrawals	0
Repayment of short-term loans	0
Net foreign exchange differences	33.469
Funding received from shareholders	0
Repayments of long-term loans, including interest	0
Payments to shareholders (dividends)	0
Payments of own shares	0
Loans granted between subsidiaries	
Total cash flow from financing	**33.469**
Total cash flow	**-19.415.694**
Cash at the beginning of the period	**57.938.876**
Cash at the beginning period of the associat	
Cash at the end of the period	**38.523.182**

Farmaceutica REMEDIA S.A.
Chairman of the Board of Administrators
“TARUS” Valentin-Norbert TARUS e.U.
by representative
Valentin-Norbert TARUS

1st Semester 2026 UNCONSOLIDATED REPORT

Board of Administrators of
Farmaceutica REMEDIA S.A.

Farmaceutica REMEDIA S.A.
Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197
Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640
remedia@remedia.ro, www.remedia.ro
Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 9.548.082
IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest
IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

1st SEMESTER 2026 UNCONSOLIDATED REPORT
According to F.S.A. Regulation No. 5/2018
Date of the report: 26.08.2026

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**
Paid-up share capital: **9.548.082 Lei**
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd.**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration
with the Trade Register Office: **J20/700/25.07.1991**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(**Registration certificate No. AC-1470-7/17.06.2021**)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **0,10 Lei**
Position in FSA Register: **1636**
Total number: **95.480.820**
FSA code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010.70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	TOTAL	**95.480.820**	**9.548.082,00 Lei**

Organized market on which securities are traded:
Bucharest Stock Exchange - Standard category
The total market value on 26.08.2026 is of 84.023.121 Lei, at a value of a 0,88 Lei/RMAH share

1. Important events to report

During the reporting period, Remedia completed the installation of a new pharmacy robot in Jibou. As a result, the company's in-house technical team has now installed and commissioned a total of 26 units, consolidating the company's position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

2. The general description of the financial position and of the issuer's performances and of its branches related to the 1st semester 2026

During the period 01.01.2026 – 30.06.2026 the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-June 2026 (Lei)	Realisations Jan-June 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	555.015	2.003.975	-72,30%
2.	Other operating revenues	2.972.976	4.343.931	-31,56%
3.	Total operating revenues	3.527.990	6.347.906	-44,42%
4.	Total operating costs *	3.812.208	4.751.802	-19,77%
5.	Operating result	-284.218	1.596.104	-117,81%
6.	Financial result	1.337.812	1.100.027	21,62%
7.	Gross result (profit)	1.053.594	2.696.132	-60,92%

* Including commercial discounts granted/received

"Other operating revenues" mainly comprise the following categories of revenues:

- collected rents – 88% out of "Other operating revenues"
- BD Rowa services – 12%

3. The financial statements as of 30.06.2026 were not audited by the independent financial auditor.

4. Economic-Financial Indicators

LIQUIDITY AND WORKING CAPITAL	30.06.2026
Current liquidity (Current assets / Current debts)	3,07
Current assets	20.737.378
Current debts	6.753.456
Degree of indebtedness (Borrowed capital / Equity x 100)	0
Borrowed capital	0,0%
Equity	56.207.959
Turnover speed for client debit items (Average customer balance /turnover *180)	141 days
Average customer balance	2.754.543
Net turnover	3.527.879
Turnover speed of stocks (average stock balance/cogs)*180	486 days
Average stock balance	967.199
Net COGS	358.273

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 141 days is a normal one under the circumstances.

4) The value of the **Nr. Of the Storage Days** indicator is in line with the nature of the company's business, being influenced by the high value of the stock represented by the BD Rowa robot. This is purchased exclusively on the basis of a firm order and an accepted quotation.

26.08.2026

Board of Administrators

Chairman
"TARUS" Valentin-Norbert TARUS e.U.
1020 Viena, Leopold-Moses Gasse, 4/42/6, Austria

FN 349134h/23.07.2010

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - unconsolidated (Lei)

	30.06.2026	30.06.2025
Net turnover	**3.527.879**	**4.717.168**
Income from the sale of goods	555.015	2.003.975
Commercial discounts granted	0	0
Income from services provided and rents	2.972.865	2.713.193
Income from real estate investments	0	
Other operating income	**111**	**1.630.738**
OPERATING INCOME - TOTAL	**3.527.990**	**6.347.906**
Expenses with materials	**604.881**	**1.387.473**
Expenses regarding goods	358.273	1.183.364
Commercial discounts received	0	0
Expenses with raw materials and consumables	162.518	120.460
Other expenses with materials (inventory objects)	13.622	13.914
Energy and water expenses	70.468	69.735
Expenses with personnel	**1.871.127**	**1.174.201**
Salaries and allowances	1.187.362	910.953
Expenses with insurance and social protection	37.592	25.598
Other personnel expenses	646.173	237.650
Amortisations and provisions	**339.084**	**688.434**
Amortisations	684.044	688.166
Net provisions	-344.971	0
Losses from receivables	11	269
Other operating expenses	**997.117**	**1.501.694**
Expenses on external services	751.355	706.947
Expenses with other taxes, charges and assimilated payments	213.968	220.275
Other expenses	31.794	574.472
OPERATING EXPENSES - TOTAL	**3.812.208**	**4.751.802**
OPERATING RESULT	**-284.218**	**1.596.104**
Financial income	**1.348.782**	**1.158.826**
Interest income	268.421	148.100
Income from exchange rate differences	1.893	10.727
Income from dividends	1.078.468	1.000.000
Advance payment discounts	0	0
Other financial income	0	0
Financial expenses	**10.970**	**58.799**
Interest expense		1.199
Operational leasing interest	1.097	57.600
Expenses from exchange rate differences	9.873	0
Discounts collected in advance	0	
Other financial expenses		
FINANCIAL RESULT	**1.337.812**	**1.100.027**
TOTAL INCOME	**4.876.772**	**7.506.732**
TOTAL EXPENSES	**3.823.178**	**4.810.601**

GROSS RESULT	**1.053.594**	**2.696.132**
Profit tax	26.834	167.787
TOTAL NET PROFIT of which distributable	**1.026.760**	**2.528.344**
Shareholders of the company	**1.026.760**	**2.528.344**
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which attributable:	**1.026.760**	**2.528.344**
Shareholders of the company	**1.026.760**	**2.528.344**
Minority interest		
Earnings per share (in Lei)		
- basic	0,0108	0,0265
- diluted	0,0108	0,0265

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - unconsolidated (Lei)

	30.06.2026	31.12.2025
ASSETS		
Fixed assets	**46.331.680**	**46.778.298**
Tangible assets	11.083.479	11.605.109
Real estate investments	34.234.480	34.234.480
Operational leasing assets	26.679	28.477
Software licences	108.260	130.449
Pharmacy licences	0	0
Participations held in group companies	602.200	602.200
Participations held in companies outside the group	130.286	130.286
Investments in jointly controlled entities accounted for using the equity method	0	
Deposits and guarantees paid	146.297	47.297
Current assets	**20.737.378**	**20.533.682**
Stocks	1.350.754	794.467
Advances granted for the purchase of inventories	2.903	2.063
Trade receivables	1.541.667	3.772.937
Other receivables	231.142	494.814
Cash and cash equivalents	17.610.912	15.469.401
Accrued expenses	**716.364**	**115.420**
TOTAL ASSETS	**67.785.423**	**67.427.400**
EQUITIES AND DEBTS		
Equities	**56.207.959**	**59.539.707**
Share capital	9.548.082	9.548.082
Share premiums	757.485	757.485
Reserves	19.565.761	17.192.330
Revaluation reserves	29.140.569	29.140.569
Current result	1.026.760	7.067.746
Retained earnings	1.045.020	1.045.019
Retained earnings - retreatment	-405.950	-340.833
Profit distribution	0	0
Own shares	-1.316.108	-1.316.108
Losses related to the issuance, redemption, sale, free transfer or cancellation of equity instruments	-107.727	-107.727
Employee benefits in the form of equity instruments	469.630	68.708
Other equity items	-3.515.563	-3.515.563
Long-term debts	**4.824.008**	**4.820.834**
Debts from long term operational leasing	27.532	24.358
Provisions		
Debts with deferred income tax	4.796.476	4.796.476
Current debts	**6.753.456**	**3.066.858**
Bank loans	0	0
Debts from financial leasing	0	0
Debts from operational leasing	1.501	6.121

Suppliers and other similar debts	238.588	700.592
Provisions	0	344.971
Current tax debts	6.621	470.324
Other short-term debts	6.251.158	1.289.262
Deferred income tax liabilities	255.588	255.588
Total debts	**11.577.464**	**7.887.692**
TOTAL EQUITIES AND DEBTS	**67.785.423**	**67.427.400**

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25th 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13th 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1st 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1st 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **April 2022**, Farmaceutica REMEDIA SA purchased a 50% participation in the share capital of the Romanian legal entity PHARMA EXPERTSPEDITION S.R.L., with registered office in Bucharest, Bd. Metalurgiei, nr. 130E, Sector 4, registered at the Commercial Register of Bucharest with nr. J40/20206/2005, with TIN 18178346, in order to develop and strengthen the distribution and logistics activity.

In **January 2025**, Farmaceutica REMEDIA SA (FR) acquired 24 per cent of the share capital of SC Novoengrama SRL, a company specialising in medical rehabilitation, which operates in the city of Cluj-Napoca.

In this context, **on 30.06.2026** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

During the first half of 2026 Farmaceutica REMEDIA S.A. did not participate in mergers.

During the same period, the company did not alienate assets of significant value (buildings, land, shares, etc.).

During the reporting period, Remedia completed the installation of a new pharmacy robot in Jibou. As a result, the company's in-house technical team has now installed and commissioned a total of 26 units, consolidating the company's position as the national leader in the automation of pharmacies, warehouses and hospital facilities.

NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counter-performance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
- Segment reporting

The company holds participations in other companies, within which it has control over the financial and operational policies. An entity is consolidated if, based on the assessment of its relations with the Company, it is found that it is controlled by the Company.

Starting with 2012, for the class of tangible assets « Lands and buildings », the Company passed from the cost-based accounting model to the reassessment model.

The financial statements on 30.06.2026 were not audited by the independent financial auditor.

NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

During the period 01.01.2026 – 30.06.2026, the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-Jun 2026 (Lei)	Realisations Jan-Jun 2025 (Lei)	Evolution 2026/2025 (%)
1.	Net sales of goods *	555.015	2.003.975	-72,30%
2.	Other operating revenues	2.972.976	4.343.931	-31,56%
3.	Total operating revenues	3.527.990	6.347.906	-44,42%
4.	Total operating costs *	3.812.208	4.751.802	-19,77%
5.	Operating result	-284.218	1.596.104	-117,81%
6.	Financial result	1.337.812	1.100.027	21,62%
7.	Gross result (profit)	1.053.594	2.696.132	-60,92%

* Including commercial discounts granted/received

“Other operating revenues” mainly comprise the following categories of revenues:

- collected rents – 88% out of “Other operating revenues”
- BD Rowa services – 12%

NOTE 4 ECONOMIC-FINANCIAL INDICATORS

	30.06.2026
Current liquidity (Current assets / Current debts)	3,07
Current assets	20.737.378
Current debts	6.753.456
Degree of indebtedness (Borrowed capital / Equity x 100)	0
Borrowed capital	0,0%
Equity	56.207.959
Turnover speed for client debit items (Average customer balance /turnover *180)	141 zile
Average customer balance	2.754.543
Net turnover	3.527.879
Turnover speed of stocks (average stock balance/cogs)*180	486 zile
Average stock balance	967.199
Net COGS	358.273

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 141 days is a normal one under the circumstances.

4) The value of the **Nr. Of the Storage Days** indicator is in line with the nature of the company's business, being influenced by the high value of the stock represented by the BD Rowa robot. This is purchased exclusively on the basis of a firm order and an accepted quotation.

NOTE 5 Reporting on activity segments (unconsolidated)

		Remedia	BD ROWA/Robots	Rents for	Provided	TOTAL *
		farmacies		spaces/auto	services	2026
Net turnover		**293.739**	**616.242**	**2.617.899**	**0**	**3.527.879**
	Income from the sale of goods	293.739	261.276			**555.015**
	Commercial discounts granted	**0**		0	0	**0**
	Income from services provided and rents	**0**	354.966	2.617.899	0	**2.972.865**
Other operating revenues		**0**			111	**111**
OPERATING REVENUES - TOTAL		**293.739**	**616.242**	**2.617.899**	**111**	**3.527.990**
						0
Expenses with goods		**242.702**	**115.571**	**0**	**0**	**358.273**
	Expenses regarding goods	242.702	115.571	0	0	**358.273**
	Commercial discounts received	0		0	0	**0**
Gross margin from sales of goods		**51.037**	**145.704**	**0**	**0**	**196.742**
						0
Other operating costs		**280.611**	**950.018**	**2.223.306**	**0**	**3.453.935**
	Direct costs	88.244	919.206	508.867	0	**1.516.317**
	Logistics costs	**0**		0	0	**0**
	Promotion costs	**0**		0	0	**0**
	Indirect costs	192.367	30.812	1.714.439	0	**1.937.618**
OPERATING EXPENSES - TOTAL		**523.313**	**1.065.589**	**2.223.306**	**0**	**3.812.208**
						0
Operating result		**-229.574**	**-449.348**	**394.592**	**111**	**-284.218**
Financial result						**1.337.812**
Gross result						**1.053.594**
	Profit tax					26.834
Net profit						**1.026.760**

NOTE 6 CAPITALS CHANGES

(unconsolidated)	Share	Legal	Revaluation	Other	Employee benefits granted	Other equity components	Share	Retained	Current	Own	TOTAL
	capital	reserves	reserves	reserves	in the form of equity instruments		premiums	earnings	result	shares	2026
Balance on 01.01.2026	**9.548.082**	**2.121.796**	**29.140.569**	**15.070.534**	**68.708**	**-3.515.563**	**757.485**	**704.186**	**7.067.746**	**-1.423.835**	**59.539.707**
											0
Profit transfer 2025 to retained earnings								7.067.746	-7.067.746		**0**
Profit distribution 2025 to dividends				0				-4.694.314			**-4.694.314**
Profit distribution 2025 to other reserves				2.373.431				-2.373.431			**0**
Profit distribution 2025 to legal reserves											**0**
Result 2026									1.026.760		**1.026.760**
Legal reserve 2025											**0**
Account closure 129											**0**
Buildings + lands outputs											**0**
Revaluation of buildings and lands											**0**
Deferred tax											**0**
Transfer reserves from funds				**0**				0			**0**
Buy own shares											**0**
Losses from the free transfer of own shares										0	**0**
Transfer of deferred tax from the revaluation reserve											**0**
Reserves – Employee Share Plan (IFRS 2)				0	400.923						**400.923**
Accounting adjustments								-65.117			**-65.117**
IFRS restatement											**0**
Balance on 30.06.2026	**9.548.082**	**2.121.796**	**29.140.569**	**17.443.965**	**469.630**	**-3.515.563**	**757.485**	**639.070**	**1.026.759**	**-1.423.835**	**56.207.959**

NOTE 7 TREASURY FLOWS STATEMENT (RON)

unconsolidated	30/06/2026
Cash flows from operating activities	
Collections from the sale of goods and from the provision of services	7.631.207
Other cash inflows	14.890
Payments to suppliers of goods and services	-4.315.747
Payments to and on behalf of employees (incl. taxes on salaries)	-1.053.989
Corporate tax payments	-527.614
Payments to other taxes and fees	-764.868
Paid interests	
Collected interests (current account)	268.421
Other cash outflows	-180.672
Total operating cash flow	**1.071.627**
Cash flow from investment activities	
Proceeds from the sale of long-term assets and financial investments	0
Collected interests (from deposits)	
Collected dividends	1.078.468
Payments for the purchase of long-term assets	
Total cash flow from investments	**1.078.468**
Cash flow from financing activities	
Short-term loan withdrawals	
Repayment of short-term loans	0
Net foreign exchange differences	-8.584
Funding received/granted	
Repayments of long-term loans, including interest	
Payments to shareholders (dividends)	0
Payments of own shares	0
Loans granted between subsidiaries	
Total cash flow from financing	**-8.584**
Total cash flow	**2.141.511**
Cash at the beginning of the period	**15.469.401**
Cash at the end of the period	**17.610.912**

Farmaceutica REMEDIA S.A.
Chairman of the Board of Administrators
“TARUS” Valentin Norbert TARUS e.U.
by representative

Valentin-Norbert TARUS

Remedia
Farmaceutica REMEDIA S.A.

Bucharest, August 26th 2026

Statement of August 26th, 2026
of responsible persons within the company
Farmaceutica REMEDIA S.A.
for the Semestrial Report 2026

In accordance with the legal provisions in force regarding the issuers and the operations with securities, the undersigned, as a responsible person within Farmaceutica REMEDIA S.A., according to my knowledge, declare the following:

1. Unconsolidated and consolidated semestrial financial statements of Farmaceutica REMEDIA S.A. ended June 30, 2026, for the first semester of the year 2026, prepared according to the applicable accounting standards, gives a correct image and in accordance with the reality of the assets, liabilities, financial position and profit and loss account.
2. The reports of the Board of Administrators include a correct analysis of the issuer's development and performances as well as a description of the main risks and uncertainties specific to the activity carried out.

Function	Name	Period of responsibility
Chairman of the Board of Administrators	„TARUS” - Valentin Norbert TARUS e.U”, reprezentata de Valentin-Norbert TARUS	01.01.2026-30.06.2026
Member of the Board of Administrators	Cristian PLOCON	01.01.2026-30.06.2026
Member of the Board of Administrators	Theodor COJOCARU-TOTH	01.05.2026 – 30.06.2026
General Manager	Roxana-Georgiana ULMEANU	01.05.2026-30.06.2026